3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Pleural Effusion, Malignant
4
Breast Neoplasms
4
Immunoglobulin Light-chain Amyloidosis
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Exanthema
2
Amyloidosis
2
Waldenstrom Macroglobulinemia
1
Urologic Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Tissue Adhesions
1
Skin Toxicity
1
Sezary Syndrome
1
Ras-wildtype Colorectal Cancer
1
Polyps
1
Polycystic Ovary Syndrome
1
Pain
1
Ovarian Neoplasms
1
Neurofibromatosis 2
1
Neoplasms, Second Primary
1
Neoplasms
1
Myoma
1
Menstruation Disturbances
1
Melanoma
1
Interventions
Peripheral Blood Stem Cell Transplantation
38
fludarabine phosphate
36
Cyclophosphamide
31
Mycophenolic Acid
28
Cyclosporine
25
Whole-Body Irradiation
24
Tacrolimus
22
Busulfan
18
Antilymphocyte Serum
18
Radiotherapy
16
Methotrexate
16
Filgrastim
14
Etoposide
13
Methylprednisolone
10
Lenalidomide
10
Bortezomib
10
Vorinostat
9
Melphalan
9
Flow Cytometry
9
Rituximab
8
Gemcitabine
8
Cord Blood Stem Cell Transplantation
7
Bexarotene
7
pembrolizumab
6
mogamulizumab
6
Alemtuzumab
6
tanespimycin
5
fludarabine
5
aldesleukin
5
Transplantation
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sezary Syndrome
×
Doxycycline
×
Clear all
NCT02341209
2021-04-27
CTCL
Rochester General Hospital
Phase 2
Terminated
1 enrolled